News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities Attorneys



2/6/2012 9:30:56 AM

DALLAS, Feb. 3, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating whether certain officers and directors of Micromet, Inc. (NASDAQ: MITI) violated shareholder protection laws by agreeing to a tender offer for $11.00 per share to Amgen. Concerned Micromet investors are encouraged to contact securities class action attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies for this potentially low buyout.

"The Wall Street Journal reported that Micromet and Amgen had a collaboration agreement to develop oncology drugs months ago," said Hamilton Lindley. "This buyout appears to be designed for Amgen to take advantage of a pipeline for a leukemia drug so that it can obtain the benefit, to the detriment of the Micromet stockholders. Our proposed shareholder lawsuit seeks to obtain a higher value for shareholders than the current buyout offer."

Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Micromet stockholders or anyone with knowledge about this acquisition should contact lawyer Hamilton Lindley at hlindley@goldfarbllp.com or 877-583-2855 with questions or concerns.

Hamilton Lindley
Goldfarb LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
www.goldfarbllp.com

SOURCE Goldfarb LLP


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES